
NASDAQHealthcareBiotechnology
Latest quote
$3.28
−$0.0791 · -2.35%
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Previous close
$3.28
−$0.0791 · -2.35%
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
58
Mixed
Risk
74
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Day range
Current $3.28
52-week range
Current $3.28
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.00
418.29% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 18, 2023 | 1:12 | — | — |
Stock split | Aug 1, 2022 | 2:25 | — | — |
Stock split | Sep 24, 2021 | 1:4 | — | — |
Stock split | Oct 23, 2019 | 1:5 | — | — |
Effective Jul 18, 2023
1:12
Effective Aug 1, 2022
2:25
Effective Sep 24, 2021
1:4
Effective Oct 23, 2019
1:5
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.